[go: up one dir, main page]

MX2014008702A - Composiciones derivadas de la quitosana. - Google Patents

Composiciones derivadas de la quitosana.

Info

Publication number
MX2014008702A
MX2014008702A MX2014008702A MX2014008702A MX2014008702A MX 2014008702 A MX2014008702 A MX 2014008702A MX 2014008702 A MX2014008702 A MX 2014008702A MX 2014008702 A MX2014008702 A MX 2014008702A MX 2014008702 A MX2014008702 A MX 2014008702A
Authority
MX
Mexico
Prior art keywords
chitosan
neoplasms
derived compositions
malignant
derived
Prior art date
Application number
MX2014008702A
Other languages
English (en)
Other versions
MX371275B (es
Inventor
Joseph Raker
Tomas Hode
Robert Nordquist
Wei Chen
Raoul Carubelli
Luciano Alleruzzo
Peter Jenkins
Kristopher Waynant
Original Assignee
Immunophotonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48799808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014008702(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunophotonics Inc filed Critical Immunophotonics Inc
Publication of MX2014008702A publication Critical patent/MX2014008702A/es
Publication of MX371275B publication Critical patent/MX371275B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Materials Engineering (AREA)
  • Electromagnetism (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención está relacionada en general con los compuestos terapéuticos que comprenden compuestos derivados de quitosana empleados junto con métodos para tratar neoplasmas, como por ejemplo, neoplasmas malignos del pulmón, tiroides y riñón, y otros tipos de neoplasmas malignos, y otros trastornos médicos.
MX2014008702A 2012-01-20 2013-01-17 Composiciones derivadas de la quitosana. MX371275B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261588783P 2012-01-20 2012-01-20
PCT/US2013/021903 WO2013109732A2 (en) 2012-01-20 2013-01-17 Chitosan-derived compositions

Publications (2)

Publication Number Publication Date
MX2014008702A true MX2014008702A (es) 2015-04-08
MX371275B MX371275B (es) 2020-01-23

Family

ID=48799808

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008702A MX371275B (es) 2012-01-20 2013-01-17 Composiciones derivadas de la quitosana.

Country Status (31)

Country Link
US (1) US20150018748A1 (es)
EP (2) EP3831393A1 (es)
JP (1) JP6180436B2 (es)
KR (5) KR20170032490A (es)
CN (2) CN104619310A (es)
AU (1) AU2013209716B2 (es)
BR (1) BR112014017426B1 (es)
CA (1) CA2861367C (es)
CL (1) CL2014001880A1 (es)
CO (1) CO7101239A2 (es)
CY (1) CY1123490T1 (es)
DK (1) DK2804611T3 (es)
EA (1) EA030148B1 (es)
EC (1) ECSP14014778A (es)
ES (1) ES2829899T3 (es)
HK (1) HK1210019A1 (es)
HR (1) HRP20201647T1 (es)
HU (1) HUE051744T2 (es)
IL (1) IL233649B (es)
LT (1) LT2804611T (es)
MX (1) MX371275B (es)
MY (1) MY191932A (es)
NZ (1) NZ628433A (es)
PE (1) PE20142325A1 (es)
PL (1) PL2804611T3 (es)
PT (1) PT2804611T (es)
RS (1) RS61257B1 (es)
SG (1) SG11201403943TA (es)
SI (1) SI2804611T1 (es)
SM (1) SMT202000637T1 (es)
WO (1) WO2013109732A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
US20190002594A1 (en) * 2014-07-16 2019-01-03 Immunophotonics, Inc. Chitosan-Derived Compositions
CN107200788B (zh) * 2017-05-11 2020-04-14 暨南大学 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
US20200010575A1 (en) * 2018-07-05 2020-01-09 Immunophotonics, Inc. Semi-synthetic biopolymers for use in treating proliferative disorders
WO2020060131A1 (ko) * 2018-09-19 2020-03-26 주식회사 엘지화학 LiOH를 포함하는 리튬 이차 전지용 전극, 그의 제조방법, 및 상기 전극을 포함하는 리튬 이차 전지
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
AU2020266676A1 (en) 2019-05-02 2021-09-30 SURGE Therapeutics, Inc. Cancer treatment
GB202007703D0 (en) * 2020-05-22 2020-07-08 Nanomerics Ltd Amphiphilic carbohydrate compounds
EP4392040A4 (en) * 2021-08-27 2025-11-12 Immunophotonics Inc Glycated chitosans for the treatment of viral infections
KR20250128337A (ko) 2022-12-20 2025-08-27 리틱스 바이오파마 에이에스 펩티드의 수성 제형을 함유하는 의료 제품
AU2023413685A1 (en) 2022-12-20 2025-06-19 Lytix Biopharma As Compositions comprising an oncolytic peptide and chitosan
CN117820043A (zh) * 2023-03-21 2024-04-05 广州优卡思农业技术有限公司 一种龙虾壳水溶性肥料及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US591200A (en) 1897-10-05 Safe-lock
US4424346A (en) * 1981-06-04 1984-01-03 Canadian Patents And Development Ltd. Derivatives of chitins, chitosans and other polysaccharides
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5214036A (en) 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5283225A (en) 1992-11-24 1994-02-01 Eastman Kodak Company Underlayer of dye-donor element for thermal dye transfer systems
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
US6316007B1 (en) * 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
JP3929491B2 (ja) 1995-04-04 2007-06-13 ウーンド・ヒーリング・オブ・オクラホマ・インコーポレーテッド イムノアジュバントを併用する光力学療法による癌治療
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
EP1152013B1 (en) 1998-11-10 2008-04-23 Netech Inc. Functional chitosan derivative
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US20040047892A1 (en) * 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
US6756363B1 (en) * 2000-11-17 2004-06-29 Wound Healing Of Oklahoma, Inc. Solutions and films of glycated chitosan
ES2622834T3 (es) * 2007-11-13 2017-07-07 Bio-Technology General (Israel) Ltd. Procedimiento de esterilización por filtración en estado diluido para biopolímeros viscoelásticos
CN101440136B (zh) * 2008-12-12 2011-07-06 中国海洋大学 胺糖化几丁聚糖复合物的制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
US9414967B2 (en) 2014-04-16 2016-08-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications

Also Published As

Publication number Publication date
CA2861367C (en) 2021-06-29
CL2014001880A1 (es) 2014-11-07
EP2804611B1 (en) 2020-09-30
PT2804611T (pt) 2020-11-12
AU2013209716A1 (en) 2014-08-28
HRP20201647T1 (hr) 2021-06-25
IL233649A0 (en) 2014-08-31
IL233649B (en) 2019-07-31
SMT202000637T1 (it) 2021-01-05
SI2804611T1 (sl) 2021-01-29
US20150018748A1 (en) 2015-01-15
KR20140117487A (ko) 2014-10-07
JP2015513522A (ja) 2015-05-14
MX371275B (es) 2020-01-23
CN104619310A (zh) 2015-05-13
SG11201403943TA (en) 2014-08-28
ECSP14014778A (es) 2016-01-29
EP3831393A1 (en) 2021-06-09
HK1210019A1 (en) 2016-04-15
EA030148B1 (ru) 2018-06-29
CY1123490T1 (el) 2022-03-24
NZ628433A (en) 2017-02-24
WO2013109732A3 (en) 2015-01-08
DK2804611T3 (da) 2020-11-09
BR112014017426A8 (pt) 2017-07-04
RS61257B1 (sr) 2021-01-29
CA2861367A1 (en) 2013-07-25
CN110038125A (zh) 2019-07-23
PL2804611T3 (pl) 2021-03-08
EP2804611A4 (en) 2016-02-17
HUE051744T2 (hu) 2021-03-29
JP6180436B2 (ja) 2017-08-16
WO2013109732A2 (en) 2013-07-25
EP2804611A2 (en) 2014-11-26
MY191932A (en) 2022-07-19
AU2013209716B2 (en) 2017-04-27
KR20170032490A (ko) 2017-03-22
CO7101239A2 (es) 2014-10-31
KR20200139254A (ko) 2020-12-11
PE20142325A1 (es) 2015-02-01
EA201491402A1 (ru) 2014-12-30
ES2829899T3 (es) 2021-06-02
BR112014017426A2 (pt) 2017-06-13
KR20180123727A (ko) 2018-11-19
LT2804611T (lt) 2020-11-25
KR20220028153A (ko) 2022-03-08
BR112014017426B1 (pt) 2021-12-28

Similar Documents

Publication Publication Date Title
MY191932A (en) Chitosan-derived compositions
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EA201590987A1 (ru) Соединения и способы их применения
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
PH12015500825B1 (en) Substituted benzene compounds
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
NZ707086A (en) Anti-cd40 antibodies and methods of use
GB201106750D0 (en) Novel compounds
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
WO2015009726A3 (en) Medical uses of cd38 agonists
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
IN2014DN09228A (es)
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MY174744A (en) Uses of bacopa monnieri extract
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
IN2013MU03429A (es)

Legal Events

Date Code Title Description
FG Grant or registration